<?xml version='1.0' encoding='utf-8'?>
<document id="16207095"><sentence text="Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy." /><sentence text="To determine the frequency of monitoring of international normalized ratio (INR) within 14 days of coprescription of warfarin and antimicrobial therapy and to evaluate differences in INR monitoring among antimicrobials" /><sentence text="" /><sentence text="Retrospective cohort study" /><sentence text="" /><sentence text="Group model health maintenance organization" /><sentence text="" /><sentence text="Patients aged 65 years or older who were taking warfarin and an antimicrobial agent" /><sentence text="" /><sentence text="Patients who received dispensings of both warfarin and an antimicrobial agent were identified" /><sentence text=" We found 2959 coprescribing instances in 1816 patients" /><sentence text=" The INR values were obtained for 2267 (77%) coprescribing situations within 14 days" /><sentence text=" Monitoring occurred more frequently (p&lt;0" /><sentence text="001) when warfarin was coprescribed with fluoroquinolones (641 [85%] of 755 situations), metronidazole (59 [81%] of 73), tetracyclines (274 [80%] of 341), or macrolides (201 [83%] of 243) than when warfarin was coprescribed with sulfonamides (35 [66%] of 53), penicillins (604 [71%] of 856), or cephalosporins (419 [71%] of 591)"><entity charOffset="89-102" id="DDI-PubMed.16207095.s14.e0" text="metronidazole" /><entity charOffset="121-134" id="DDI-PubMed.16207095.s14.e1" text="tetracyclines" /><entity charOffset="229-241" id="DDI-PubMed.16207095.s14.e2" text="sulfonamides" /><entity charOffset="260-271" id="DDI-PubMed.16207095.s14.e3" text="penicillins" /><entity charOffset="295-309" id="DDI-PubMed.16207095.s14.e4" text="cephalosporins" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e0" e2="DDI-PubMed.16207095.s14.e0" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e0" e2="DDI-PubMed.16207095.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e0" e2="DDI-PubMed.16207095.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e0" e2="DDI-PubMed.16207095.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e0" e2="DDI-PubMed.16207095.s14.e4" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e1" e2="DDI-PubMed.16207095.s14.e1" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e1" e2="DDI-PubMed.16207095.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e1" e2="DDI-PubMed.16207095.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e1" e2="DDI-PubMed.16207095.s14.e4" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e2" e2="DDI-PubMed.16207095.s14.e2" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e2" e2="DDI-PubMed.16207095.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e2" e2="DDI-PubMed.16207095.s14.e4" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e3" e2="DDI-PubMed.16207095.s14.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s14.e3" e2="DDI-PubMed.16207095.s14.e4" /></sentence><sentence text=" Among monitored patients, a higher proportion of monitoring (p&lt;0" /><sentence text="001) occurred within 7 days for patients prescribed antifungals (87%), fluoroquinolones (88%), tetracyclines (82%), metronidazole (86%), sulfonamides (86%), or macrolides (85%) than for patients prescribed cephalosporins (68%) or penicillins (75%)"><entity charOffset="95-108" id="DDI-PubMed.16207095.s16.e0" text="tetracyclines" /><entity charOffset="116-129" id="DDI-PubMed.16207095.s16.e1" text="metronidazole" /><entity charOffset="137-149" id="DDI-PubMed.16207095.s16.e2" text="sulfonamides" /><entity charOffset="206-220" id="DDI-PubMed.16207095.s16.e3" text="cephalosporins" /><entity charOffset="230-241" id="DDI-PubMed.16207095.s16.e4" text="penicillins" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e0" e2="DDI-PubMed.16207095.s16.e0" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e0" e2="DDI-PubMed.16207095.s16.e1" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e0" e2="DDI-PubMed.16207095.s16.e2" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e0" e2="DDI-PubMed.16207095.s16.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e0" e2="DDI-PubMed.16207095.s16.e4" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e1" e2="DDI-PubMed.16207095.s16.e1" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e1" e2="DDI-PubMed.16207095.s16.e2" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e1" e2="DDI-PubMed.16207095.s16.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e1" e2="DDI-PubMed.16207095.s16.e4" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e2" e2="DDI-PubMed.16207095.s16.e2" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e2" e2="DDI-PubMed.16207095.s16.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e2" e2="DDI-PubMed.16207095.s16.e4" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e3" e2="DDI-PubMed.16207095.s16.e3" /><pair ddi="false" e1="DDI-PubMed.16207095.s16.e3" e2="DDI-PubMed.16207095.s16.e4" /></sentence><sentence text="" /><sentence text="Most older patients coprescribed warfarin and an antimicrobial in our organization had INR monitoring within 7 days" /><sentence text=" This is consistent with appropriate practice to manage a risk of clinically important drug-drug interaction between an antimicrobial agent and warfarin" /><sentence text=" Prospective identification of patients requiring INR monitoring after coprescription of interacting drugs by using merged administrative pharmacy and laboratory data should be further evaluated as a tool to improve clinical outcomes" /><sentence text="" /></document>